Cited by 336Epigenetics and DNA MethylationCancer-related gene regulationChromatin Remodeling and Cancer

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Qi, Wei, Zhao, Kehao, Gu, Justin, Huang, Ying, Wang, Youzhen, Zhang, Hailong, Zhang, Man, Zhang, Jeff, Yu, Zhengtian, Li, Ling, Teng, Lin, Chuai, Shannon, Zhang, Chao, Zhao, Mengxi, Chan, HoMan, Chen, Zijun, Fang, Douglas, Fei, Qi, Feng, Leying, Feng, Lijian, Gao, Yuan, Ge, Hui, Ge, Xinjian, Li, Guobin, Lingel, Andreas, Lin, Ying, Liu, Yueqin, Luo, Fangjun, Shi, Minlong, Wang, Long, Wang, Zhaofu, Yu, Yanyan, Zeng, Jue, Zeng, Chenhui, Zhang, Lijun, Zhang, Qiong, Zhou, Shaolian, Oyang, Counde, Atadja, Peter, Li, En·2017·Nature Chemical Biology

DOI 10.1038/nchembio.2304

Open this paper in CoChat — free account

Abstract

Polycomb repressive complex 2 (PRC2) consists of three core subunits, EZH2, EED and SUZ12, and plays pivotal roles in transcriptional regulation. The catalytic subunit EZH2 methylates histone H3 lysine 27 (H3K27), and its activity is further enhanced by the binding of EED to trimethylated H3K27 (H3K27me3). Small-molecule inhibitors that compete with the cofactor S-adenosylmethionine (SAM) have been reported. Here we report the discovery of EED226, a potent and selective PRC2 inhibitor that directly binds to the H3K27me3 binding pocket of EED. EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity. EED226 shows similar activity to SAM-competitive inhibitors in blocking H3K27 methylation of PRC2 target genes and inducing regression of human lymphoma xenograft tumors. Interestingly, EED226 also effectively inhibits PRC2 containing a mutant EZH2 protein resistant to SAM-competitive inhibitors. Together, we show that EED226 inhibits PRC2 activity via an allosteric mechanism and offers an opportunity for treatment of PRC2-dependent cancers.

Integrity signals

Registry

Crossref · 10.1038/nchembio.2304

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
The CCP4 suite: programs for protein crystallography
Number Collaborative Computational Project (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,317
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Self-citation
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,719
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., de Azambuja, E., Aura, C. M., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,324
Role of the polycomb protein EED in the propagation of repressive histone marks
Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury, W. J., Voigt, P., Martin, S. R., Taylor, W. R., Marco, V. D., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,281
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196

Flagged first, then by citations

Show all 54 references

Sorted by citations

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
EZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 980
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A. J., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 671
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 523
Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
Biswas, S., & Rao, C. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.021 · Cited by 442
The roles of Polycomb repressive complexes in mammalian development and cancer
Piunti, A., & Shilatifard, A. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00341-1 · Cited by 420
WD40 repeat domain proteins: a novel target class?
Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335
Inhibitors of Protein Methyltransferases and Demethylases
Kanıskan, H. Ü., Martini, M. L., & Jin, J. J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 327
Chemical and Biochemical Perspectives of Protein Lysine Methylation
Luo, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00008 · Cited by 295
Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways
Ito, T., Teo, Y. V., Evans, S. A., Neretti, N., & Sedivy, J. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.002 · Cited by 265
PRC2 is high maintenancePreprint
Yu, J.-R., Lee, C., Oksuz, O., Stafford, J. M., & Reinberg, D. (2019) · Genes & Development · doi:10.1101/gad.325050.119 · Cited by 267
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 262
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease
Bhat, K. P., Kanıskan, H. Ü., Jin, J. J., & Gozani, O. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00108-x · Cited by 250
Targeting EZH2 in cancer therapy
Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 232
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex
Hsu, J. H.-R., Rasmusson, T., Robinson, J., Pachl, F., Read, J., Kawatkar, S., O’ Donovan, D. H., Bagal, S., Code, E., Rawlins, P., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.004 · Cited by 202
Enhancer of zeste homolog 2 (EZH2) inhibitors
Gulati, N., Béguelin, W., & Giulino-Roth, L. G. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1430795 · Cited by 205
Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancerPreprint
Bracken, A. P., Brien, G. L., & Verrijzer, C. P. (2019) · Genes & Development · doi:10.1101/gad.326066.119 · Cited by 203
Regulation, functions and transmission of bivalent chromatin during mammalian development
Macrae, T. A., Fothergill-Robinson, J., & Ramalho‐Santos, M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00518-2 · Cited by 196
Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction
Guo, Y., Zhao, S., & Wang, G. G. (2021) · Trends in Genetics · doi:10.1016/j.tig.2020.12.006 · Cited by 199
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Nepali, K., & Liou, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 187
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Potjewyd, F., Turner, A. W., Beri, J., Rectenwald, J. M., Norris-Drouin, J. L., Cholensky, S. H., Margolis, D. M., Pearce, K. H., Herring, L. E., & James, L. I. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.006 · Cited by 181
The long and short non-coding RNAs modulating EZH2 signaling in cancer
Mirzaei, S., Gholami, M. H., Hushmandi, K., Hashemi, F., Zabolian, A., Cañadas, I., Zarrabi, A., Nabavi, N., Aref, A. R., Crea, F., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01235-1 · Cited by 163
Self-citation
RNA-modifying proteins as anticancer drug targets
Boriack‐Sjodin, P. A., Ribich, S. A., & Copeland, R. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.71 · Cited by 157
Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
Bisserier, M., & Wajapeyee, N. (2018) · Blood · doi:10.1182/blood-2017-08-804344 · Cited by 150
The role of histone methylation in the development of digestive cancers: a potential direction for cancer management
Chen, Y., Ren, B., Yang, J., Wang, H., Yang, G., Xu, R., You, L., & Zhao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00252-1 · Cited by 145
Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2
Lee, C., Holder, M., Grau, D., Saldaña-Meyer, R., Yu, J.-R., Ganai, R. A., Zhang, J., Wang, M., LeRoy, G., Dobenecker, M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.019 · Cited by 150
Self-citation
Engaging chromatin: PRC2 structure meets function
Chammas, P., Mocavini, I., & Croce, L. D. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0615-2 · Cited by 149
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate ( R )-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2 H )-one (PF-06821497)
Kung, P., Bingham, P., Brooun, A., Collins, M. R., Deng, Y., Dinh, D. M., Fan, C., Gajiwala, K. S., Grantner, R., Gukasyan, H. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01375 · Cited by 139
A chemical biology toolbox to study protein methyltransferases and epigenetic signaling
Scheer, S., Ackloo, S. Z., Medina, T. D. S., Schapira, M., Li, F., Ward, J. A., Lewis, A. M., Northrop, J. P., Richardson, P. L., Kanıskan, H. Ü., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07905-4 · Cited by 131
Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin
Lee, C., Yu, J.-R., Kumar, S., Jin, Y., LeRoy, G., Bhanu, N. V., Kaneko, S., Garcia, B. A., Hamilton, A. D., & Reinberg, D. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.020 · Cited by 140
Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease
Majumder, S., Thieme, K., Batchu, S. N., Alghamdi, T. A., Bowskill, B. B., Kabir, M. G., Liu, Y., Advani, S. L., White, K., Geldenhuys, L., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95946 · Cited by 125
Self-citation
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds
Fioravanti, R., Stazi, G., Zwergel, C., Valente, S., & Mai, A. (2018) · The Chemical Record · doi:10.1002/tcr.201800091 · Cited by 121
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
Jones, B. A., Varambally, S., & Arend, R. C. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0437 · Cited by 118
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review
Rugo, H. S., Jacobs, I. A., Sharma, S., Scappaticci, F. A., Paul, T. A., Jensen-Pergakes, K., & Malouf, G. G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01379-x · Cited by 109
EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
Li, B., & Chng, W. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0814-6 · Cited by 101
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes
Sengupta, S., Das, S., Crespo, Â. C., Cornel, A. M., Patel, A. G., Mahadevan, N. R., Campisi, M., Ali, A. K., Sharma, B., Rowe, J. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00427-5 · Cited by 101
Epigenetic regulation in cancer therapy: From mechanisms to clinical advances
Tao, L., Zhou, Y., Luo, Y., Qiu, J., Xiao, Y., Zou, J., Zhang, Y., Liu, X., Yang, X., Gou, K., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.59 · Cited by 95
Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens
Arbuckle, J. H., Gardina, P. J., Gordon, D. N., Hickman, H. D., Yewdell, J. W., Pierson, T. C., Myers, T. G., & Kristie, T. M. (2017) · mBio · doi:10.1128/mbio.01141-17 · Cited by 83
Polycomb repressive 2 complex—Molecular mechanisms of function
Kouznetsova, V. L., Tchekanov, A., Li, X., Yan, X., & Tsigelny, I. F. (2019) · Protein Science · doi:10.1002/pro.3647 · Cited by 82
Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3
Ma, Z., Huang, H., Wang, J., Zhou, Y., Pu, F., Zhao, Q., Peng, P., Hui, B., Ji, H., & Wang, K. (2017) · Oncotarget · doi:10.18632/oncotarget.20359 · Cited by 77
Targeting Histone Methylation in Cancer
McCabe, M. T., Mohammad, H. P., Barbash, O., & Kruger, R. G. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000283 · Cited by 76
EZH2-Mediated microRNA-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer.
Ma, J., Zhang, J., Weng, Y., & Wang, J. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0109 · Cited by 70
Self-citation
Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer
Liu, Q., Wang, G., Li, Q., Jiang, W., Kim, J., Wang, R., Zhu, S. L., Wang, X., Lin, Y., Yang, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32118 · Cited by 69
Self-citation
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Wang, C., Zhang, Y., Wang, J., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113906 · Cited by 73
Fragment-to-Lead Medicinal Chemistry Publications in 2017
Mortenson, P. N., Erlanson, D. A., de Esch, I. J. P., Jahnke, W., & Johnson, C. N. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01472 · Cited by 69
Lineage specification and pluripotency revealed by transcriptome analysis from oocyte to blastocyst in pig
Kong, Q., Xu, Y., Zhang, H., Liu, S., Zhao, J., Zhang, J., Weng, X., Jin, J., & Liu, Z. (2019) · The FASEB Journal · doi:10.1096/fj.201901818rr · Cited by 65
Self-citation
Triazole-fused pyrimidines in target-based anticancer drug discovery
Dai, X., Xue, L.-P., Ji, S., Zhou, Y., Gao, Y., Zheng, Y., Liu, H., & Liu, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115101 · Cited by 64
Self-citation
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
Radko-Juettner, S., Yue, H., Myers, J., Carter, R. D., Robertson, A. N., Mittal, P., Zhu, Z., Hansen, B. S., Donovan, K. A., Hunkeler, M., et al. (2024) · Nature · doi:10.1038/s41586-024-07250-1 · Cited by 68
A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion
Cai, X.-C., Zhang, T., Kim, E., Jiang, M. Z., Wang, K., Wang, J., Chen, S., Zhang, N., Wu, H., Li, F., et al. (2019) · eLife · doi:10.7554/elife.47110 · Cited by 62
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies
Huang, Y. R., Sendzik, M., Zhang, J., Gao, Z., Sun, Y., Wang, L., Gu, J., Zhao, K., Yu, Z., Zhang, L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02148 · Cited by 61
Self-citation
Polycomb repressive complex 2 shields naïve human pluripotent cells from trophectoderm differentiation
Kumar, B. M., Navarro, C., Winblad, N., Schell, J. P., Zhao, C., Weltner, J., Baqué-Vidal, L., Mantero, A. S., Sophie Petropoulos, A., Lanner, F., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00916-w · Cited by 63
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer
Martin, M. C., Zeng, G., Yu, J., & Schiltz, G. E. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01344 · Cited by 64
Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7
Lamb, K. N., Bsteh, D., Dishman, S. N., Moussa, H. F., Fan, H., Stuckey, J. I., Norris, J. L., Cholensky, S. H., Li, D., Wang, J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.013 · Cited by 61
Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective
Webb, T., Craigon, C., & Ciulli, A. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128653 · Cited by 58
Genome-Wide Estrogen Receptor Activity in Breast Cancer
Farcas, A. M., Nagarajan, S., Cosulich, S. C., & Carroll, J. S. (2020) · Endocrinology · doi:10.1210/endocr/bqaa224 · Cited by 60
Targeting non-bromodomain chromatin readers
Arrowsmith, C. H., & Schapira, M. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0290-2 · Cited by 57
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
Wang, B., Liu, Y., Liao, Z., Wu, H., Zhang, B., & Zhang, L. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00405-2 · Cited by 59
Self-citation
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Kazansky, Y., Cameron, D., Mueller, H. S., Demarest, P., Zaffaroni, N., Arrighetti, N., Zuco, V., Kuwahara, Y., Somwar, R., Ladanyi, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0110 · Cited by 59
PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components
Bashore, F. M., Foley, C. A., Ong, H. W., Rectenwald, J. M., Hanley, R. P., Norris-Drouin, J. L., Cholensky, S. H., Mills, C. A., Pearce, K. H., Herring, L. E., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00804 · Cited by 58
Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor
de Freitas, R. F., Ivanochko, D., & Schapira, M. (2019) · Molecules · doi:10.3390/molecules24244492 · Cited by 57
An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response
Dong, H., Liu, S., Zhang, X., Chen, S., Kang, L., Chen, Y., Ma, S., Fu, X., Liu, Y., Zhang, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0428 · Cited by 53
Self-citation
Polycomb Repressive Complex 2 Modulation through the Development of EZH2–EED Interaction Inhibitors and EED Binders
Tomassi, S., Romanelli, A., Zwergel, C., Valente, S., & Mai, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00226 · Cited by 57
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED
Li, L., Zhang, H., Zhang, M., Zhao, M., Feng, L., Luo, X., Gao, Z., Huang, Y. R., Ardayfio, O., Zhang, J.-H., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169855 · Cited by 54
Self-citation
EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation
Herviou, L., Jourdan, M., Martinez, A., Cavalli, G., & Moreaux, J. (2019) · Leukemia · doi:10.1038/s41375-019-0392-1 · Cited by 58
Epigenetic small molecule modulators of histone and DNA methylation
Hauser, A., Robaa, D., & Jung, M. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.03.003 · Cited by 50
Drugging histone methyltransferases in cancer
Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 51
EZH2 inhibitors: a patent review (2014-2016)
Stazi, G., Zwergel, C., Mai, A., & Valente, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1316976 · Cited by 49
Drug Discovery and Chemical Biology of Cancer Epigenetics
Ribich, S. A., Harvey, D. M., & Copeland, R. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.020 · Cited by 50
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 49
Lysine methyltransferase inhibitors: where we are now
Feoli, A., Viviano, M., Cipriano, A., Milite, C., Castellano, S., & Sbardella, G. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00196e · Cited by 50
Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation
Zaware, N., & Zhou, M. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.012 · Cited by 49
Persistent epigenetic reprogramming of sweet taste by diet
Vaziri, A., Khabiri, M., Genaw, B. T., May, C. E., Freddolino, P. L., & Dus, M. (2020) · Science Advances · doi:10.1126/sciadv.abc8492 · Cited by 49
Targeting epigenetic machinery: Emerging novel allosteric inhibitors
Ye, F., Huang, J. L., Wang, H., Luo, C., & Zhao, K. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107406 · Cited by 47
Self-citation
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)
Dockerill, M., Gregson, C. L., & O’Donovan, D. H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1841167 · Cited by 46
Disease Association and Druggability of WD40 Repeat Proteins
Song, R., Wang, Z.-D., & Schapira, M. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00451 · Cited by 45
Self-citation
Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer
Chu, L., Qu, Y.-X., An, Y., Hou, L., Li, J., Li, W., Fan, G., Song, B., Li, E., Zhang, L., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04601-6 · Cited by 47
Self-citation
Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45
Recent progress in developing selective inhibitors of protein methyltransferases
Kanıskan, H. Ü., & Jin, J. J. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.013 · Cited by 46
Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma
Dupéré-Richer, D., & Licht, J. D. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000358 · Cited by 43
Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction
Du, D., Xu, D., Zhu, L., Stazi, G., Zwergel, C., Liu, Y., Luo, Z., Li, Y., Zhang, Y., Zhu, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02261 · Cited by 45
Self-citation
PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function
Liu, X., & Liu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894585 · Cited by 48
Exploiting Epigenetic Alterations in Prostate Cancer
Baumgart, S. J., & Haendler, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051017 · Cited by 44
PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor
Diehl, K. L., Ge, E. J., Weinberg, D. N., Jani, K. S., Allis, C. D., & Muir, T. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911775116 · Cited by 41
Polycomb-lamina antagonism partitions heterochromatin at the nuclear periphery
Siegenfeld, A. P., Roseman, S. A., Roh, H., Lue, N. Z., Wagen, C., Zhou, E., Johnstone, S. E., Aryee, M. J., & Liau, B. B. (2022) · Nature Communications · doi:10.1038/s41467-022-31857-5 · Cited by 40
Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities
McBride, M. J., & Kadoch, C. (2018) · The Journal of Pathology · doi:10.1002/path.5042 · Cited by 41
The control of polycomb repressive complexes by long noncoding RNAs
Trotman, J. B., Braceros, K. C. A., Cherney, R. E., Murvin, M. M., & Calabrese, J. M. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1657 · Cited by 37
EZH2: An Accomplice of Gastric Cancer
Yu, W., Liu, N., Song, X., Chen, L., Wang, M., Xiao, G., Li, T., Wang, Z., & Zhang, Y. (2023) · Cancers · doi:10.3390/cancers15020425 · Cited by 37
Self-citation
Targeting protein methylation: from chemical tools to precision medicines
Dilworth, D., & Baršytė-Lovejoy, D. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03147-9 · Cited by 35
A positive feedback loop between EZH2 and NOX4 regulates nucleus pulposus cell senescence in age-related intervertebral disc degeneration
Liu, C., Liu, L., Yang, M., Li, B., Yi, J., Ai, X., Zhang, Y., Huang, B. S., Li, C., Feng, C., et al. (2020) · Cell Division · doi:10.1186/s13008-020-0060-x · Cited by 35
EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development
Rej, R. K., Wang, C., Lü, J., Wang, M., Petrunak, E. M., Zawacki, K. P., McEachern, D., Fernández‐Salas, E., Yang, C., Wang, L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00479 · Cited by 35
Self-citation
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
Li, X., Gera, L., Zhang, S., Chen, Y., Lou, L., Wilson, L. M., Xie, Z., Sautto, G. A., Liu, D., Danaher, A., et al. (2021) · Theranostics · doi:10.7150/thno.49235 · Cited by 35
Chemically induced degradation of epigenetic targets
Kabir, M., Yu, X., Kanıskan, H. Ü., & Jin, J. J. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00100h · Cited by 36
Structure-based view of the druggable genome
Wang, J., Yazdani, S., Han, A., & Schapira, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.02.006 · Cited by 36
Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression
Rej, R. K., Wang, C., Lü, J., Wang, M., Petrunak, E. M., Zawacki, K. P., McEachern, D., Yang, C., Wang, L., Li, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01059 · Cited by 34
Self-citation
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry
Patel, A. J., Warda, S., Mååg, J. L. V., Misra, R., Miranda-Román, M. A., Pachai, M. R., Lee, C. J., Li, D., Wang, N., Bayshtok, G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1671 · Cited by 36
Tackling malignant melanoma epigenetically: histone lysine methylation
Orouji, E., & Utikal, J. S. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0583-z · Cited by 33
Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer
Soshnev, A. A., Allis, C. D., Cesarman, E., & Melnick, A. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2619 · Cited by 30
Methyllysine binding domains: Structural insight and small molecule probe development
Teske, K. A., & Hadden, M. K. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.047 · Cited by 32

Authors: Qi, W., Zhao, K., Gu, J., Huang, Y., Wang, Y., Zhang, H., Zhang, M., Zhang, J., Yu, Z., Li, L., Teng, L., Chuai, S., Zhang, C., Zhao, M., Chan, H., Chen, Z., Fang, D., Fei, Q., Feng, L., Feng, L., Gao, Y., Ge, H., Ge, X., Li, G., Lingel, A., Lin, Y., Liu, Y., Luo, F., Shi, M., Wang, L., Wang, Z., Yu, Y., Zeng, J., Zeng, C., Zhang, L., Zhang, Q., Zhou, S., Oyang, C., Atadja, P., & Li, E.
Affiliations: Novartis Institutes for BioMedical Research (CH)
Corresponding author: Li, En
ORCID: Qi, Wei
Zhao, Kehao
Huang, Ying
Zhang, Hailong
Zhang, Man
Zhang, Jeff
Li, Ling
Zhao, Mengxi
Chen, Zijun
Fang, Douglas
Ge, Hui
Lingel, Andreas
Lin, Ying
Liu, Yueqin
Wang, Zhaofu
Yu, Yanyan
Zhang, Qiong
Li, En
Venue: Nature Chemical Biology
Publisher: Springer Science and Business Media LLC
Published: 2017-01-30
Volume: 13
Issue: 4
Pages: 381-388
ISSN: 1552-4450 (ISSN-L)
1552-4469
DOI: 10.1038/nchembio.2304
OpenAlex: W2582081516
Cited by: 316
References: 54
Citations by year: 2026: 18 · 2025: 21 · 2024: 39 · 2023: 27 · 2022: 42 · 2021: 33 · 2020: 37 · 2019: 40 · 2018: 32 · 2017: 26
FWCI: 15.64
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Chemical Biology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: polycomb repressive complex 2, EED, H3K27me3, allosteric inhibition, EZH2, histone methyltransferase, small molecule inhibitors, lymphoma, transcriptional regulation, conformational change
MeSH terms: Allosteric Regulation, Animals, Antineoplastic Agents, Binding Sites, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Female, Histones, Humans, Lysine, Mice, Inbred BALB C, Mice, Nude, Models, Molecular, Neoplasms, Experimental, Structure-Activity Relationship, Sulfones, Triazoles, Tumor Cells, Cultured, Molecular Structure, Cell Line, Tumor, Cell Proliferation, Mice, Polycomb Repressive Complex 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks